ANZCTR search results

STRIVE – Sexually Transmitted infections in Remote communities: ImproVed and enhanced primary health care services is a new trial which aims to reduce levels of STIs in 21 or more participating ‘trial clusters’ over a five year period. STRIVE is 5 year project in partnership between the National Centre in HIV Epidemiology and Clinical Research, the Menzies School of Health Research and government and community organisations in NT, WA and QLD. Funding for the trial was awarded by the National Health and Medical Research Council (NHMRC Project Grant, Application ID: 568806, 2009-2013). Proposed clusters of communities will be located in the NT, WA and QLD. STRIVE will test whether the development and then implementation of a Sexual Health Quality Improvement Program tailored for primary health care centres will improve STI service delivery and assist these services on reaching best practice in STI control. STRIVE will also provide incentive payments for achieving aspects of best practice in STI care.

Weight loss and under-nutrition is common in older people and associated with poor outcomes. This includes increased rates of hospital admissions. In a pilot study of ndernourished older, community dwelling people we found that daily treatment for one year with a combination of testosterone tablets and a nutritional supplement produced a significant reduction in hospitalizations. We propose a larger, multicentre study to explore and hopefully confirm this exciting, potentially important finding.

Small amounts of sweet tasting sugar water reduces pain in babies during painful blood tests and injections. We do not know if sugar also reduces pain in toddlers and young children. This project will help to determine if small amounts of sugar water reduce pain in toddlers during their immunisations and venepuncture and if sucking on a lollypop helps to reduce pain in pre-school children between 3 and 5 years of age during their injections for immunisation. The immunisation part of this study will be done in the Royal Children’s Hospital Immunisation Centre where mothers and fathers bring their children in to have their scheduled childhood immunisations done. The part of the study examining sucrose efficacy in hospitalized toddlers during venepuncture will be conducted in Canada, at CHEO in a surgical ward.

This trial is a prospective evaluation of a new method of diagnosing coronary calcium, using standard non contrast calcium score as the reference standard.

Acromioclavicular (AC) joint pathology is a common cause of shoulder pain. The location of pain originating from the AC joint can be diverse and patients are often not able to identify the exact location. In most patients the pain will be located in an area bounded by the mid-part of the clavicle and the deltoid insertion, but the pain has also been shown to radiate to the radial side of the forearm into the thumb. AC joint pathology can occur in isolation, but is often associated with other causes of shoulder pain, such as subacromial impingement or rotator cuff pathology. Surgical treatment of other causes of shoulder pain can affect the AC joint, and arthroscopic acromioplasty may have detrimental effects on an already compromised AC joint. Conversely, residual AC joint pathology has been shown to have a negative effect on the outcome of surgery to the rotator cuff. Detection of AC joint pathology is therefore crucial in the treatment of patients with any type of shoulder problem and various clinical tests have been described to asses AC joint pathology. The primary aim of this study was to assess the diagnostic sensitivity of the BvR (Bell-van Riet) test, when compared with other tests.

To investigate whether supplementation with combined fish oil/CoQ10 alters hepatic triglyceride concentration, composition and cardiovascular risk factors in overweight men.

Current therapy for irritable bowel syndrome is suboptimal. Recent studies have suggested that small intestinal bacterial overgrowth may be present and that its treatment may have therapeutic benefit. The primary aim is to examine whether the effect of Yakult on a breath hydrogen test feature of bacterial overgorwoth that was seen in the pilot study is reproducible and specific to the study treatment, or just a chance observation. The secondary aims were to define the effect of Yakult on the rate at which the stomach empties, to compare the effects on gut symptoms of Yakult, placebo and Yakult withdrawal, and to examine the association of change in breath test patterns with changes in gut symptoms. In addition, because bacterial overgrowth is said to be causally associated with fructose malabsorption, another aim is to examine the effect of Yakult and the changes in breath test patterns with changes in fructose absorption and malabsorption. The major study hypotheses are that Yakult corrects small intestinal bacterial overgrowth and that this correction is associated with improvement in symptoms of irritable bowel syndrome

The primary purpose of the study is to assess microbial contamination of antibacterial contact lens cases when used in conjunction with marketed contact lenses worn on a daily wear and monthly replacement schedule and to compare the results to a historical control. Hypothesis: antibacterial lens cases will have less contamination inside the lens storage case than a regular lens case

This study looks at the effectiveness of the drugs lapatinib and vinorelbine in treating breast cancer (HER2/neu positive type) which has spread to distant sites and has been previously treated. Who is it for? You can join this study if you are a woman with Her2-positive breast cancer which has spread to distant sites and has progressed after initial treatment with trastuzumab-based treatment followed by lapatinib-capecitabine. Trial details Participants will receive lapatinib (1250 mg orally once daily) continuously and vinorelbine (20 mg/m2 (intra venous) on Day 1 and Day 8, of a 21-day cycle. Treatment will continue until any major toxic symptoms occur, or the disease or symptoms progress. If the cancer fails to respond, the patient will stop the study treatment and enter into the Survival Follow Up, where the cancer will be managed at the investigator’s discretion. Regular tumour scans will be used to monitor the disease. Scans will be completed 6 weekly until week 24 and then every 12 weeks thereafter. Quality of Life questionnaire will be completed by the patient to evaluate their pain and pain-relief use during the treatment period. The best combination of drugs to use after HER2 positive breast cancer has progressed on lapatinib-capecitabine is not known. Vinorelbine and lapatinib both have activity for the treatment of breast cancer. The study aims to evaluate the effect of this combination of drugs on survival rates and quality of life. Throughout the study the safety of the patient will be continually reviewed by the study doctor (physical examination, vital signs, side effects assessment & regular safety blood tests). Cardiac safety will be monitored by serial multi-gated acquisition scan (MUGA) or Echocardiograph at weeks 12, 24 & 52. For the first 5 patients enrolled in the study the Data Safety Monitoring Committee will review all side effects experienced during the course of cycle 1 and 2. This is to ensure that this treatment combination does not cause unacceptable side effects in a group of patients who have already received several lines of anti-cancer treatment. Overall survival will be assessed by contacting the patients every 3 months during the Survival follow up part of the study.

To investigate the feasibility of a community-based randomised control trial exploring the practices employed by general practitioners and exercise physiologists in the management of overweight/obese patients, and their effect on weight reduction and cardiovascular risk factors.